APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Drugs for Herpes Labialis (Oral Herpes)

Herpes Labialis (Oral Herpes) is a type of herpes simplex occurring on the lip, i.e. an infection caused by herpes simplex virus (HSV). An outbreak typically causes small blisters or sores on or around the mouth. The sores typically heal within 2–3 weeks, but the herpes virus remains dormant in the facial nerves, following orofacial infection, periodically reactivating (in symptomatic people) to create sores in the same area of the mouth or face at the site of the original infection.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Herpes Labialis (Oral Herpes) is a type of herpes simplex occurring on the lip, i.e. an infection caused by herpes simplex virus (HSV). An outbreak typically causes small blisters or sores on or around the mouth. The sores typically heal within 2–3 weeks, but the herpes virus remains dormant in the facial nerves, following orofacial infection, periodically reactivating (in symptomatic people) to create sores in the same area of the mouth or face at the site of the original infection.

Selected research

Market Outlook & Growth Opportunities

Global Drugs for Herpes Labialis (Oral Herpes) Market Outlook and Growth Opportunities 2026

Report ID 17398635049 January 2026204 pages

Choose your research edition.

Industry ResearchDrugs for Herpes Labialis (Oral Herpes) Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal Drugs for Herpes Labialis (Oral Herpes) Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Drugs for Herpes Labialis (Oral Herpes) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drugs for Herpes Labialis (Oral Herpes) Market Outlook and Growth Opportunities 2026204 pages · $4,250 USDMarket Analysis & ForecastGlobal Drugs for Herpes Labialis (Oral Herpes) Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

Herpes Labialis (Oral Herpes) is a type of herpes simplex occurring on the lip, i.e. an infection caused by herpes simplex virus (HSV). An outbreak typically causes small blisters or sores on or around the mouth. The sores typically heal within 2–3 weeks, but the herpes virus remains dormant in the facial nerves, following orofacial infection, periodically reactivating (in symptomatic people) to create sores in the same area of the mouth or face at the site of the original infection.

Global Drugs for Herpes Labialis (Oral Herpes) key players include GSK, Novartis, Teva, Mylan, Cadila, etc. Global top five manufacturers hold a share about 55%. North America is the largest market, with a share about 35%, followed by Europe, with a share about 30 percent. In terms of product, Rx Drugs is the largest segment, with a share about 90%. And in terms of application, the largest application is Oral, followed by External Use, and Injection, etc.

This report provides an overview of the global Drugs for Herpes Labialis (Oral Herpes) market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

Read the full market overview

The study covers key producers of Drugs for Herpes Labialis (Oral Herpes) and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Drugs for Herpes Labialis (Oral Herpes) revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Drugs for Herpes Labialis (Oral Herpes) market.

Drugs for Herpes Labialis (Oral Herpes) Segment by Company

GSK

Novartis

Teva

Mylan

Cadila

Apotex

Daewoong Pharmaceutical

Livzon

Luoxin

Med shine

Bayer (Campho Phenique)

Blistex

Kelun

Hikma

Haiwang

Carmex

Cipher

Drugs for Herpes Labialis (Oral Herpes) Segment by Type

Aciclovir

Valacyclovir

Famciclovir

Docosanol

Other

Drugs for Herpes Labialis (Oral Herpes) Segment by Application

External Use

Oral

Injection

Drugs for Herpes Labialis (Oral Herpes) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Drugs for Herpes Labialis (Oral Herpes) status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Drugs for Herpes Labialis (Oral Herpes) key companies, revenue, market share, and recent developments.

3. To split the Drugs for Herpes Labialis (Oral Herpes) breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Drugs for Herpes Labialis (Oral Herpes) market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Drugs for Herpes Labialis (Oral Herpes) significant trends, drivers, influence factors in global and regions.

6. To analyze Drugs for Herpes Labialis (Oral Herpes) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs for Herpes Labialis (Oral Herpes) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drugs for Herpes Labialis (Oral Herpes) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs for Herpes Labialis (Oral Herpes).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Drugs for Herpes Labialis (Oral Herpes) industry.

Chapter 3: Detailed analysis of Drugs for Herpes Labialis (Oral Herpes) company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Drugs for Herpes Labialis (Oral Herpes) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Drugs for Herpes Labialis (Oral Herpes) in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Drugs for Herpes Labialis (Oral Herpes) Industry Trends Table 2. Drugs for Herpes Labialis (Oral Herpes) Industry Drivers Table 3. Drugs for Herpes Labialis (Oral Herpes) Industry Opportunities and Challenges Table 4. Drugs for Herpes Labialis (Oral Herpes) Industry Restraints Table 5. Global Drugs for Herpes Labialis (Oral Herpes) Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Drugs for Herpes Labialis (Oral Herpes) Revenue Share by Company (2021-2026) Table 7. Global Drugs for Herpes Labialis (Oral Herpes) Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Drugs for Herpes Labialis (Oral Herpes) Key Company Manufacturing Base & Headquarters Table 9. Global Drugs for Herpes Labialis (Oral Herpes) Company, Product Type & Application Table 10. Global Drugs for Herpes Labialis (Oral Herpes) Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Drugs for Herpes Labialis (Oral Herpes) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Aciclovir Table 15. Significant Companies of Valacyclovir Table 16. Significant Companies of Famciclovir Table 17. Significant Companies of Docosanol Table 18. Significant Companies of Other Table 19. Global Drugs for Herpes Labialis (Oral Herpes) Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Drugs for Herpes Labialis (Oral Herpes) Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global Drugs for Herpes Labialis (Oral Herpes) Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Type (2021-2026) Table 23. Global Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Type (2027-2032) Table 24. Significant Companies of External Use Table 25. Significant Companies of Oral Table 26. Significant Companies of Injection Table 27. Global Drugs for Herpes Labialis (Oral Herpes) Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Drugs for Herpes Labialis (Oral Herpes) Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Drugs for Herpes Labialis (Oral Herpes) Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Application (2021-2026) Table 31. Global Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Application (2027-2032) Table 32. Global Drugs for Herpes Labialis (Oral Herpes) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Drugs for Herpes Labialis (Oral Herpes) Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Region (2021-2026) Table 35. Global Drugs for Herpes Labialis (Oral Herpes) Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Region (2027-2032) Table 37. Global Drugs for Herpes Labialis (Oral Herpes) Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Drugs for Herpes Labialis (Oral Herpes) Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Drugs for Herpes Labialis (Oral Herpes) Sales Value Market Share by Country (2021-2026) Table 40. Global Drugs for Herpes Labialis (Oral Herpes) Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Drugs for Herpes Labialis (Oral Herpes) Sales Value Market Share by Country (2027-2032) Table 42. GSK Company Information Table 43. GSK Business Overview Table 44. GSK Drugs for Herpes Labialis (Oral Herpes) Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. GSK Drugs for Herpes Labialis (Oral Herpes) Product Portfolio Table 46. GSK Recent Development Table 47. Novartis Company Information Table 48. Novartis Business Overview Table 49. Novartis Drugs for Herpes Labialis (Oral Herpes) Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Novartis Drugs for Herpes Labialis (Oral Herpes) Product Portfolio Table 51. Novartis Recent Development Table 52. Teva Company Information Table 53. Teva Business Overview Table 54. Teva Drugs for Herpes Labialis (Oral Herpes) Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. Teva Drugs for Herpes Labialis (Oral Herpes) Product Portfolio Table 56. Teva Recent Development Table 57. Mylan Company Information Table 58. Mylan Business Overview Table 59. Mylan Drugs for Herpes Labialis (Oral Herpes) Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. Mylan Drugs for Herpes Labialis (Oral Herpes) Product Portfolio Table 61. Mylan Recent Development Table 62. Cadila Company Information Table 63. Cadila Business Overview Table 64. Cadila Drugs for Herpes Labialis (Oral Herpes) Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Cadila Drugs for Herpes Labialis (Oral Herpes) Product Portfolio Table 66. Cadila Recent Development Table 67. Apotex Company Information Table 68. Apotex Business Overview Table 69. Apotex Drugs for Herpes Labialis (Oral Herpes) Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Apotex Drugs for Herpes Labialis (Oral Herpes) Product Portfolio Table 71. Apotex Recent Development Table 72. Daewoong Pharmaceutical Company Information Table 73. Daewoong Pharmaceutical Business Overview Table 74. Daewoong Pharmaceutical Drugs for Herpes Labialis (Oral Herpes) Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Daewoong Pharmaceutical Drugs for Herpes Labialis (Oral Herpes) Product Portfolio Table 76. Daewoong Pharmaceutical Recent Development Table 77. Livzon Company Information Table 78. Livzon Business Overview Table 79. Livzon Drugs for Herpes Labialis (Oral Herpes) Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Livzon Drugs for Herpes Labialis (Oral Herpes) Product Portfolio Table 81. Livzon Recent Development Table 82. Luoxin Company Information Table 83. Luoxin Business Overview Table 84. Luoxin Drugs for Herpes Labialis (Oral Herpes) Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Luoxin Drugs for Herpes Labialis (Oral Herpes) Product Portfolio Table 86. Luoxin Recent Development Table 87. Med shine Company Information Table 88. Med shine Business Overview Table 89. Med shine Drugs for Herpes Labialis (Oral Herpes) Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Med shine Drugs for Herpes Labialis (Oral Herpes) Product Portfolio Table 91. Med shine Recent Development Table 92. Bayer (Campho Phenique) Company Information Table 93. Bayer (Campho Phenique) Business Overview Table 94. Bayer (Campho Phenique) Drugs for Herpes Labialis (Oral Herpes) Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 95. Bayer (Campho Phenique) Drugs for Herpes Labialis (Oral Herpes) Product Portfolio Table 96. Bayer (Campho Phenique) Recent Development Table 97. Blistex Company Information Table 98. Blistex Business Overview Table 99. Blistex Drugs for Herpes Labialis (Oral Herpes) Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 100. Blistex Drugs for Herpes Labialis (Oral Herpes) Product Portfolio Table 101. Blistex Recent Development Table 102. Kelun Company Information Table 103. Kelun Business Overview Table 104. Kelun Drugs for Herpes Labialis (Oral Herpes) Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 105. Kelun Drugs for Herpes Labialis (Oral Herpes) Product Portfolio Table 106. Kelun Recent Development Table 107. Hikma Company Information Table 108. Hikma Business Overview Table 109. Hikma Drugs for Herpes Labialis (Oral Herpes) Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 110. Hikma Drugs for Herpes Labialis (Oral Herpes) Product Portfolio Table 111. Hikma Recent Development Table 112. Haiwang Company Information Table 113. Haiwang Business Overview Table 114. Haiwang Drugs for Herpes Labialis (Oral Herpes) Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 115. Haiwang Drugs for Herpes Labialis (Oral Herpes) Product Portfolio Table 116. Haiwang Recent Development Table 117. Carmex Company Information Table 118. Carmex Business Overview Table 119. Carmex Drugs for Herpes Labialis (Oral Herpes) Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 120. Carmex Drugs for Herpes Labialis (Oral Herpes) Product Portfolio Table 121. Carmex Recent Development Table 122. Cipher Company Information Table 123. Cipher Business Overview Table 124. Cipher Drugs for Herpes Labialis (Oral Herpes) Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 125. Cipher Drugs for Herpes Labialis (Oral Herpes) Product Portfolio Table 126. Cipher Recent Development Table 127. Research Programs/Design for This Report Table 128. Authors List of This Report Table 129. Secondary Sources Table 130. Primary Sources List of Figures Figure 1. Drugs for Herpes Labialis (Oral Herpes) Product Image Figure 2. Global Drugs for Herpes Labialis (Oral Herpes) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drugs for Herpes Labialis (Oral Herpes) Market Size (2021-2032) & (US$ Million) Figure 4. Global Drugs for Herpes Labialis (Oral Herpes) Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Aciclovir Image Figure 8. Valacyclovir Image Figure 9. Famciclovir Image Figure 10. Docosanol Image Figure 11. Other Image Figure 12. Global Drugs for Herpes Labialis (Oral Herpes) Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Drugs for Herpes Labialis (Oral Herpes) Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Type (2021-2032) Figure 15. External Use Image Figure 16. Oral Image Figure 17. Injection Image Figure 18. Global Drugs for Herpes Labialis (Oral Herpes) Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Drugs for Herpes Labialis (Oral Herpes) Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Application (2021-2032) Figure 21. Global Drugs for Herpes Labialis (Oral Herpes) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Drugs for Herpes Labialis (Oral Herpes) Sales Value (2021-2032) & (US$ Million) Figure 24. North America Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Drugs for Herpes Labialis (Oral Herpes) Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Drugs for Herpes Labialis (Oral Herpes) Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Drugs for Herpes Labialis (Oral Herpes) Sales Value (2021-2032) & (US$ Million) Figure 30. South America Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Drugs for Herpes Labialis (Oral Herpes) Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Drugs for Herpes Labialis (Oral Herpes) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Drugs for Herpes Labialis (Oral Herpes) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Drugs for Herpes Labialis (Oral Herpes) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Drugs for Herpes Labialis (Oral Herpes) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Drugs for Herpes Labialis (Oral Herpes) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Drugs for Herpes Labialis (Oral Herpes) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Drugs for Herpes Labialis (Oral Herpes) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Drugs for Herpes Labialis (Oral Herpes) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Drugs for Herpes Labialis (Oral Herpes) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Drugs for Herpes Labialis (Oral Herpes) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Drugs for Herpes Labialis (Oral Herpes) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Drugs for Herpes Labialis (Oral Herpes) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Drugs for Herpes Labialis (Oral Herpes) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Drugs for Herpes Labialis (Oral Herpes) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Drugs for Herpes Labialis (Oral Herpes) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Drugs for Herpes Labialis (Oral Herpes) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Drugs for Herpes Labialis (Oral Herpes) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Drugs for Herpes Labialis (Oral Herpes) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Drugs for Herpes Labialis (Oral Herpes) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Drugs for Herpes Labialis (Oral Herpes) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Drugs for Herpes Labialis (Oral Herpes) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Drugs for Herpes Labialis (Oral Herpes) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Drugs for Herpes Labialis (Oral Herpes) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Drugs for Herpes Labialis (Oral Herpes) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Drugs for Herpes Labialis (Oral Herpes) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Drugs for Herpes Labialis (Oral Herpes) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Drugs for Herpes Labialis (Oral Herpes) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Drugs for Herpes Labialis (Oral Herpes) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Aciclovir
  • Valacyclovir
  • Famciclovir
  • Docosanol
  • Other
Applications
  • External Use
  • Oral
  • Injection
Companies covered
  • GSK
  • Novartis
  • Teva
  • Mylan
  • Cadila
  • Apotex
  • Daewoong Pharmaceutical
  • Livzon
  • Luoxin
  • Med shine
  • Bayer (Campho Phenique)
  • Blistex
  • Kelun
  • Hikma
  • Haiwang
  • Carmex
  • Cipher

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Drugs for Herpes Labialis (Oral Herpes) Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Drugs for Herpes Labialis (Oral Herpes) Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Drugs for Herpes Labialis (Oral Herpes) Market Dynamics
  1. 2.1 Drugs for Herpes Labialis (Oral Herpes) Industry Trends
  2. 2.2 Drugs for Herpes Labialis (Oral Herpes) Industry Drivers
  3. 2.3 Drugs for Herpes Labialis (Oral Herpes) Industry Opportunities and Challenges
  4. 2.4 Drugs for Herpes Labialis (Oral Herpes) Industry Restraints
3 Drugs for Herpes Labialis (Oral Herpes) Market by Company
  1. 3.1 Global Drugs for Herpes Labialis (Oral Herpes) Company Revenue Ranking in 2025
  2. 3.2 Global Drugs for Herpes Labialis (Oral Herpes) Revenue by Company (2021-2026)
  3. 3.3 Global Drugs for Herpes Labialis (Oral Herpes) Company Ranking (2024-2026)
  4. 3.4 Global Drugs for Herpes Labialis (Oral Herpes) Company Manufacturing Base and Headquarters
  5. 3.5 Global Drugs for Herpes Labialis (Oral Herpes) Company Product Type and Application
  6. 3.6 Global Drugs for Herpes Labialis (Oral Herpes) Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Drugs for Herpes Labialis (Oral Herpes) Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Drugs for Herpes Labialis (Oral Herpes) Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Drugs for Herpes Labialis (Oral Herpes) Market by Type
  1. 4.1 Drugs for Herpes Labialis (Oral Herpes) Type Introduction
  2. 4.1.1 Aciclovir
  3. 4.1.2 Valacyclovir
  4. 4.1.3 Famciclovir
  5. 4.1.4 Docosanol
  6. 4.1.5 Other
  7. 4.2 Global Drugs for Herpes Labialis (Oral Herpes) Sales Value by Type
  8. 4.2.1 Global Drugs for Herpes Labialis (Oral Herpes) Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Drugs for Herpes Labialis (Oral Herpes) Sales Value by Type (2021-2032)
  10. 4.2.3 Global Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Type (2021-2032)
5 Drugs for Herpes Labialis (Oral Herpes) Market by Application
  1. 5.1 Drugs for Herpes Labialis (Oral Herpes) Application Introduction
  2. 5.1.1 External Use
  3. 5.1.2 Oral
  4. 5.1.3 Injection
  5. 5.2 Global Drugs for Herpes Labialis (Oral Herpes) Sales Value by Application
  6. 5.2.1 Global Drugs for Herpes Labialis (Oral Herpes) Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Drugs for Herpes Labialis (Oral Herpes) Sales Value by Application (2021-2032)
  8. 5.2.3 Global Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Application (2021-2032)
6 Drugs for Herpes Labialis (Oral Herpes) Regional Value Analysis
  1. 6.1 Global Drugs for Herpes Labialis (Oral Herpes) Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Drugs for Herpes Labialis (Oral Herpes) Sales Value by Region (2021-2032)
  3. 6.2.1 Global Drugs for Herpes Labialis (Oral Herpes) Sales Value by Region: 2021-2026
  4. 6.2.2 Global Drugs for Herpes Labialis (Oral Herpes) Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Drugs for Herpes Labialis (Oral Herpes) Sales Value (2021-2032)
  7. 6.3.2 North America Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Drugs for Herpes Labialis (Oral Herpes) Sales Value (2021-2032)
  10. 6.4.2 Europe Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Drugs for Herpes Labialis (Oral Herpes) Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Drugs for Herpes Labialis (Oral Herpes) Sales Value (2021-2032)
  16. 6.6.2 South America Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Drugs for Herpes Labialis (Oral Herpes) Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Country, 2025 VS 2032
7 Drugs for Herpes Labialis (Oral Herpes) Country-level Value Analysis
  1. 7.1 Global Drugs for Herpes Labialis (Oral Herpes) Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Drugs for Herpes Labialis (Oral Herpes) Sales Value by Country (2021-2032)
  3. 7.2.1 Global Drugs for Herpes Labialis (Oral Herpes) Sales Value by Country (2021-2026)
  4. 7.2.2 Global Drugs for Herpes Labialis (Oral Herpes) Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Drugs for Herpes Labialis (Oral Herpes) Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Drugs for Herpes Labialis (Oral Herpes) Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Drugs for Herpes Labialis (Oral Herpes) Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Drugs for Herpes Labialis (Oral Herpes) Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Drugs for Herpes Labialis (Oral Herpes) Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Drugs for Herpes Labialis (Oral Herpes) Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Drugs for Herpes Labialis (Oral Herpes) Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Drugs for Herpes Labialis (Oral Herpes) Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Drugs for Herpes Labialis (Oral Herpes) Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Drugs for Herpes Labialis (Oral Herpes) Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Drugs for Herpes Labialis (Oral Herpes) Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Drugs for Herpes Labialis (Oral Herpes) Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Drugs for Herpes Labialis (Oral Herpes) Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Drugs for Herpes Labialis (Oral Herpes) Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Drugs for Herpes Labialis (Oral Herpes) Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Drugs for Herpes Labialis (Oral Herpes) Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Drugs for Herpes Labialis (Oral Herpes) Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Drugs for Herpes Labialis (Oral Herpes) Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Drugs for Herpes Labialis (Oral Herpes) Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Drugs for Herpes Labialis (Oral Herpes) Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Drugs for Herpes Labialis (Oral Herpes) Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Drugs for Herpes Labialis (Oral Herpes) Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Drugs for Herpes Labialis (Oral Herpes) Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Drugs for Herpes Labialis (Oral Herpes) Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Drugs for Herpes Labialis (Oral Herpes) Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Drugs for Herpes Labialis (Oral Herpes) Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Drugs for Herpes Labialis (Oral Herpes) Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Drugs for Herpes Labialis (Oral Herpes) Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Drugs for Herpes Labialis (Oral Herpes) Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 GSK
  2. 8.1.1 GSK Company Information
  3. 8.1.2 GSK Business Overview
  4. 8.1.3 GSK Drugs for Herpes Labialis (Oral Herpes) Revenue and Gross Margin (2021-2026)
  5. 8.1.4 GSK Drugs for Herpes Labialis (Oral Herpes) Product Portfolio
  6. 8.1.5 GSK Recent Developments
  7. 8.2 Novartis
  8. 8.2.1 Novartis Company Information
  9. 8.2.2 Novartis Business Overview
  10. 8.2.3 Novartis Drugs for Herpes Labialis (Oral Herpes) Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Novartis Drugs for Herpes Labialis (Oral Herpes) Product Portfolio
  12. 8.2.5 Novartis Recent Developments
  13. 8.3 Teva
  14. 8.3.1 Teva Company Information
  15. 8.3.2 Teva Business Overview
  16. 8.3.3 Teva Drugs for Herpes Labialis (Oral Herpes) Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Teva Drugs for Herpes Labialis (Oral Herpes) Product Portfolio
  18. 8.3.5 Teva Recent Developments
  19. 8.4 Mylan
  20. 8.4.1 Mylan Company Information
  21. 8.4.2 Mylan Business Overview
  22. 8.4.3 Mylan Drugs for Herpes Labialis (Oral Herpes) Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Mylan Drugs for Herpes Labialis (Oral Herpes) Product Portfolio
  24. 8.4.5 Mylan Recent Developments
  25. 8.5 Cadila
  26. 8.5.1 Cadila Company Information
  27. 8.5.2 Cadila Business Overview
  28. 8.5.3 Cadila Drugs for Herpes Labialis (Oral Herpes) Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Cadila Drugs for Herpes Labialis (Oral Herpes) Product Portfolio
  30. 8.5.5 Cadila Recent Developments
  31. 8.6 Apotex
  32. 8.6.1 Apotex Company Information
  33. 8.6.2 Apotex Business Overview
  34. 8.6.3 Apotex Drugs for Herpes Labialis (Oral Herpes) Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Apotex Drugs for Herpes Labialis (Oral Herpes) Product Portfolio
  36. 8.6.5 Apotex Recent Developments
  37. 8.7 Daewoong Pharmaceutical
  38. 8.7.1 Daewoong Pharmaceutical Company Information
  39. 8.7.2 Daewoong Pharmaceutical Business Overview
  40. 8.7.3 Daewoong Pharmaceutical Drugs for Herpes Labialis (Oral Herpes) Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Daewoong Pharmaceutical Drugs for Herpes Labialis (Oral Herpes) Product Portfolio
  42. 8.7.5 Daewoong Pharmaceutical Recent Developments
  43. 8.8 Livzon
  44. 8.8.1 Livzon Company Information
  45. 8.8.2 Livzon Business Overview
  46. 8.8.3 Livzon Drugs for Herpes Labialis (Oral Herpes) Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Livzon Drugs for Herpes Labialis (Oral Herpes) Product Portfolio
  48. 8.8.5 Livzon Recent Developments
  49. 8.9 Luoxin
  50. 8.9.1 Luoxin Company Information
  51. 8.9.2 Luoxin Business Overview
  52. 8.9.3 Luoxin Drugs for Herpes Labialis (Oral Herpes) Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Luoxin Drugs for Herpes Labialis (Oral Herpes) Product Portfolio
  54. 8.9.5 Luoxin Recent Developments
  55. 8.10 Med shine
  56. 8.10.1 Med shine Company Information
  57. 8.10.2 Med shine Business Overview
  58. 8.10.3 Med shine Drugs for Herpes Labialis (Oral Herpes) Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Med shine Drugs for Herpes Labialis (Oral Herpes) Product Portfolio
  60. 8.10.5 Med shine Recent Developments
  61. 8.11 Bayer (Campho Phenique)
  62. 8.11.1 Bayer (Campho Phenique) Company Information
  63. 8.11.2 Bayer (Campho Phenique) Business Overview
  64. 8.11.3 Bayer (Campho Phenique) Drugs for Herpes Labialis (Oral Herpes) Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Bayer (Campho Phenique) Drugs for Herpes Labialis (Oral Herpes) Product Portfolio
  66. 8.11.5 Bayer (Campho Phenique) Recent Developments
  67. 8.12 Blistex
  68. 8.12.1 Blistex Company Information
  69. 8.12.2 Blistex Business Overview
  70. 8.12.3 Blistex Drugs for Herpes Labialis (Oral Herpes) Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Blistex Drugs for Herpes Labialis (Oral Herpes) Product Portfolio
  72. 8.12.5 Blistex Recent Developments
  73. 8.13 Kelun
  74. 8.13.1 Kelun Company Information
  75. 8.13.2 Kelun Business Overview
  76. 8.13.3 Kelun Drugs for Herpes Labialis (Oral Herpes) Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Kelun Drugs for Herpes Labialis (Oral Herpes) Product Portfolio
  78. 8.13.5 Kelun Recent Developments
  79. 8.14 Hikma
  80. 8.14.1 Hikma Company Information
  81. 8.14.2 Hikma Business Overview
  82. 8.14.3 Hikma Drugs for Herpes Labialis (Oral Herpes) Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Hikma Drugs for Herpes Labialis (Oral Herpes) Product Portfolio
  84. 8.14.5 Hikma Recent Developments
  85. 8.15 Haiwang
  86. 8.15.1 Haiwang Company Information
  87. 8.15.2 Haiwang Business Overview
  88. 8.15.3 Haiwang Drugs for Herpes Labialis (Oral Herpes) Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Haiwang Drugs for Herpes Labialis (Oral Herpes) Product Portfolio
  90. 8.15.5 Haiwang Recent Developments
  91. 8.16 Carmex
  92. 8.16.1 Carmex Company Information
  93. 8.16.2 Carmex Business Overview
  94. 8.16.3 Carmex Drugs for Herpes Labialis (Oral Herpes) Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Carmex Drugs for Herpes Labialis (Oral Herpes) Product Portfolio
  96. 8.16.5 Carmex Recent Developments
  97. 8.17 Cipher
  98. 8.17.1 Cipher Company Information
  99. 8.17.2 Cipher Business Overview
  100. 8.17.3 Cipher Drugs for Herpes Labialis (Oral Herpes) Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Cipher Drugs for Herpes Labialis (Oral Herpes) Product Portfolio
  102. 8.17.5 Cipher Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst